bluebird bio Inc. (BLUE)

120.70
NASDAQ : Health Technology
Prev Close 122.14
Day Low/High 119.41 / 126.29
52 Wk Low/High 120.02 / 236.17
Avg Volume 665.20K
Exchange NASDAQ
Shares Outstanding 54.16M
Market Cap 6.61B
EPS -7.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing

Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing

Charts are pointing the way to an upside recovery for this stock.

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Total SA, Bluebird Bio, U.S. Silica Holdings, Nucor, International Paper, Nokia, Alibaba.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

Bluebird Bio Presents Updated Data From Phase 2/3 Starbeam Study Of Investigational Lenti-D™ Gene Therapy For CALD And Initial Data From Observational Study ALD-103 Of Allogeneic Hematopoietic Stem Cell Transplant In CALD At 2018 SSIEM

Bluebird Bio Presents Updated Data From Phase 2/3 Starbeam Study Of Investigational Lenti-D™ Gene Therapy For CALD And Initial Data From Observational Study ALD-103 Of Allogeneic Hematopoietic Stem Cell Transplant In CALD At 2018 SSIEM

bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the Phase 2/3 Starbeam study (ALD-102) of its investigational Lenti-D™ gene therapy in boys 17 years of age and under with cerebral adrenoleukodystrophy (CALD), and initial data from...

Bluebird Bio To Present At Investor Conferences In September

Bluebird Bio To Present At Investor Conferences In September

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Citi 13 th Annual Biotech Conference, Wednesday, September 5, 10:30 a.

Bluebird Bio And Gritstone Oncology Announce Strategic Collaboration To Develop Novel Cancer Cell Therapies

Bluebird Bio And Gritstone Oncology Announce Strategic Collaboration To Develop Novel Cancer Cell Therapies

bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc.

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its clinical development program for its investigational Lenti-D™ gene therapy in pediatric patients with cerebral adrenoleukodystrophy (CALD) will be presented at the Society for the Study of...

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2018.

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters' full exercise of...

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β 0/β 0 genotype, was granted an accelerated...

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Diplomacy must precede presidential threats.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock.

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral...

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

Bluebird Bio Presents New Data From Northstar (HGB-204) And Northstar-2 (HGB-207) Studies Of LentiGlobin™ Gene Therapy In Patients With Transfusion-Dependent β-Thalassemia At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207)...

Bluebird Bio Announces Investor Events In June

Bluebird Bio Announces Investor Events In June

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference, Thursday, June 7, at 10:00 a.

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

FDA Grants Breakthrough Therapy Designation To Lenti-D™ For The Treatment Of Cerebral Adrenoleukodystrophy

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

Bluebird Bio To Present New Data From LentiGlobinTM Transfusion-Dependent β-Thalassemia And Severe Sickle Cell Disease Clinical Studies At Annual Congress Of The European Hematology Association

bluebird bio, Inc. ( Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral presentations at the 23 rd Congress of the...

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

Bluebird Bio To Present Updated Clinical Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti- BCMA CAR T Cell Therapy In Patients With Late Stage Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE) announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology...

Chart of the Day: BLUE

The setup on bluebird bio is nice, with the stock overbought but not yet overheated.

Bluebird Bio To Present At Investor Conferences In May

Bluebird Bio To Present At Investor Conferences In May

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank's 43 rd Annual Health Care Conference, Wednesday, May 9, at 10:00 a.

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports First Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2018.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

TheStreet Quant Rating: D+ (Sell)